2023
DOI: 10.1016/j.ejogrb.2023.04.014
|View full text |Cite
|
Sign up to set email alerts
|

The efficacy of human papillomavirus prophylactic vaccination after conization in preventing cervical intraepithelial neoplasia recurrence: A prospective observational study in China

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(3 citation statements)
references
References 31 publications
0
2
0
Order By: Relevance
“…Chen et al's prospective cohort study, with a 2-year follow-up, investigated the vaccine's influence on CIN2+ recurrence [15]. The analysis, which included HPV testing at 6 months, 1 year, and 2 years, defined recurrence through histologically confirmed CIN2+.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Chen et al's prospective cohort study, with a 2-year follow-up, investigated the vaccine's influence on CIN2+ recurrence [15]. The analysis, which included HPV testing at 6 months, 1 year, and 2 years, defined recurrence through histologically confirmed CIN2+.…”
Section: Discussionmentioning
confidence: 99%
“…Emerging research suggests that the HPV vaccine has the potential to prevent recurrence of high-grade cervical dysplasia post-conization [15][16][17][18], and yet there is a lack of consensus or national guidelines endorsing post-treatment HPV vaccination for CIN2+ [19]. Consequently, the decision to recommend vaccination post-conization is left to individual gynecologists, which, combined with out-of-pocket costs [14], leads to disparities in vaccine uptake among treated women.…”
Section: Introductionmentioning
confidence: 99%
“…Emerging research suggests the HPV vaccine has potential to prevent recurrence of high-grade cervical dysplasia post-conization [15][16][17][18], yet there is a lack of consensus or national guidelines endorsing post-treatment HPV vaccination for CIN2+ [19]. Consequently, the decision to recommend vaccination post-conization is left to individual gynecologists, which combined with out-of-pocket costs [14], leads to disparities in vaccine uptake among treated women.…”
Section: Introductionmentioning
confidence: 99%